U.S., Nov. 26 -- ClinicalTrials.gov registry received information related to the study (NCT07247097) titled 'ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma' on Nov. 19.
Brief Summary: This research study is being done to compare the efficacy and safety of the combination of elranatamab, lenalidomide, bortezomib, dexamethasone versus the combination of daratumumab, lenalidomide, bortezomib, dexamethasone for patients with newly diagnosed, transplant ineligible/deferred multiple myeloma.
Study Start Date: April 15, 2026
Study Type: INTERVENTIONAL
Condition:
Multiple Myeloma
Newly Diagnosed Multiple Myeloma
Transplant Ineligible
Newly Diagnosed Mult...